Ying-Hsia Chu, MD
2021 Dr. L. Clarke, Jr. and Elaine F. Stout Award
Dr. Chu received her medical degree from the National Taiwan University. She first developed an interest in oncologic molecular diagnostics while working as a visiting research intern at the Institution of Bioengineering and Nanotechnology (IBN) under the supervision of Dr. Min-Han Tan, then a Principal Research Scientist at IBN and currently CEO of Lucence Diagnostics. Her work at IBN focused on the pharmacogenetics of the tyrosine kinase inhibitor (TKI) therapy and developing genetic predictive models for the clinical outcome and TKI toxicities in renal cancer patients, leading to two publications in PLoS One and European Urology.
Dr. Chu then moved to the United States for an anatomic/clinical pathology residency at the University of Wisconsin in Madison, WI, where she worked with Dr. Ricardo V. Lloyd on elucidating the expression and clinical implications of non-coding RNAs in thyroid cancers. After completing residency, she moved to the Massachusetts General Hospital in Boston, where she was mentored by Drs. Peter M. Sadow, William C. Faquin and Vania Nose on studying the genetics of thyroid cancers. She was the lead author on two recently published papers on kinase fusion-driven thyroid carcinomas (KFTC) in Modern Pathology, which provided practical insights into the genomic landscape of KFTC with detailed correlations to TKI treatment response, resulting in the discovery of several novel genetic markers of TKI efficacy and resistance, as well as an algorithmic histomorphologic approach for microscopic triaging of cases for molecular testing.
Dr. Chu is currently a clinical fellow in Molecular Genetic Pathology at the Memorial Sloan Kettering Cancer Center with ongoing projects in the development and validation of diagnostic molecular assays for solid and hematologic neoplasms.